fig5
![Tumour suppressor microRNAs contribute to drug resistance in malignant pleural mesothelioma by targeting anti-apoptotic pathways](https://image.oaes.cc/ca271f5c-e5ae-4a38-affc-14fce5487e58/3235.fig.5.jpg)
Figure 5. Drug sensitivities following BCL2 knockdown. A: Cells were transfected with BCL2 siRNAs (siRNA-1 and siRNA-2 at 0.5 nmol/L and 1 nmol/L) or a control (1 nmol/L). After 24 h MSTO parental (blue) and MSTO-GemR, MSTO-CisR and MSTO-VinoR resistant cell lines (red), were treated with 2-fold serial dilutions of gemcitabine, cisplatin or vinorelbine respectively. Cells were assayed for proliferation 96 h following drug treatment. Drug and siRNA treated cells were normalised to siRNA treatment alone (siRNA or control transfected = 100%). Data are mean ± SD of duplicate measurements and are representative of 3 experiments producing similar results; B: The average changes of chemotherapeutic IC50 values induced by BCL2 siRNA transfection, across 3 replicate experiments, were depicted as a ratio of the IC50 values from siRNA transfected cells compared to those transfected with a control siRNA. Data is the average of 3 replicate experiments ± SEM. *P < 0.05 (two-tailed independent samples t-test)